N/A N=290 REVEAL III: Risk Evaluation and Education for Alzheimer's Disease
Alzheimer Disease
Primary: Center for Epidemiological Studies-Depression Scale (CES-D) — 4.8; 7.0; 6.4; 5.5 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=89 Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease
Genetic Risk for Alzheimer's Disease
Primary: Change in BOLD Response From Baseline to 24 Weeks During Functional Magnetic Resonance Imaging - Left Posterior Cingulate BOLD Signal at 24 Weeks, Adjusting for Baseline…
N/A N=114 Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Mild Cognitive Impairment
Primary: Geriatric Depression Scale — 2.6; 2.1; 2.8; 1.9 score on a scale
N/A N=61 Dementia Risk and Dynamic Response to Exercise
Alzheimer Disease 2 Due to Apoe4 Isoform · Healthy Aging
Primary: Cerebral Blood Flow Area Under Curve — 715; 751 mL/100g tissue
N/A N=20 SHARE(D) Stage II: Alzheimer's Risk Disclosure Protocol Piloting
Mild Cognitive Impairment · Healthy Aging
Primary: Comprehension/Recall of Results - Personal Information Score - PARTICIPANT — 82.40; 94.60; 69.40; 90.80 percentage correct
Phase 4 N=199 The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease
Alzheimer's Disease
Primary: CERAD-K (the Korean Version of the Consortium to Establish a Registry for Alzheimer's Disease) — 8.28; 7.31; 17.86; 10.62 Units on Scale
Phase 3 N=262 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
Alzheimers Disease · Dementia · Alzheimers Disease, Familial
Primary: Assess Cognitive Efficacy in Individuals With Mutations Causing Dominantly Inherited AD as Measured by the DIAN-Multivariate Cognitive Endpoint (DIAN-MCE); — 1.063…
N/A N=223 Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
Macular Degeneration
Primary: Age in Study Participants — 70.6; 77.8 years
Phase 3 N=325 An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
Early Alzheimer's Disease
Primary: Primary Cognitive Efficacy Endpoint (ADAS-Cog13) — 4.40; 3.89 Score on a scale — p=0.6058
Phase 3 N=579 Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline (W0) in Mean ADAS-Cog Total Score at W24 as a Function of APOE e4 Status in Apolipoprotein epsilon4 (APOE e4) Negative Cohort — 1.6; -0.2; 0.6; 0.9…
Phase 2 N=20 Effect of Insulin Sensitizer Metformin on AD Biomarkers
Alzheimer's Disease · Vascular Dementia · Dementia
Primary: Word List Memory Total - ADAS-cog — 14.35; 14.7; 15.1; 14.67 Words recalled
Phase 2 N=119 Resveratrol for Alzheimer's Disease
Alzheimer's Disease
Primary: Number of Adverse Events — 355; 302 number of AEs
N/A N=200 Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease
Coronary Heart Disease, Susceptibility to, 5 · Prediabetic State
Primary: Dietary Intake as Measured by Percent Energy From Fat — 33.75; 34.9; 33.72; 35.05 percent energy from fat — p=0.1073
Phase 1 N=25 Developing Clinical Tools to Communicate Genetic Risk for Individuals Who Are Clinical High Risk for Psychosis
Psychosis
Primary: Change From Baseline in Perceived Treatment Efficacy — 2.6; 1.6; 0.5; 0.5 score on a scale
N/A N=119 Exercise for Brain Health in the Fight Against Alzheimer's Disease
Healthy Cognition
Primary: Rey Auditory Verbal Learning Test Sum of Trials 1-5 — 49.7; 47.6; 51.6; 49.4 Sum of words recalled Trials 1 to 5
N/A N=1,822 Caregiver Outcomes of Alzheimer's Disease Screening
Alzheimer Disease
Primary: Short Form Health Survey (SF-36) — 48.4; 47.8; 48.8; 44.7 score on a scale
Phase 4 N=17 Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease
Alzheimer's Disease
Primary: N-acetylaspartate — 1.35; 1.86; 1.58; 1.26 NAA/creatine Ratio
Phase 2 N=50 Riluzole in Mild Alzheimer's Disease
Alzheimer's Disease
Primary: Imaging Biomarkers FDG-PET SUVR in Regions of Interest — -0.048; -0.005; -0.032; -0.007 Standardized Uptake Value Ratios (SUVRs)
N/A N=9 Genetic and Neural Factors in Alcohol-Related Cognition
Alcohol Abuse
Primary: Changes in Alcohol-influenced Behavior — 1.56; 1.49 units on a scale
N/A N=148 STIM+: PET Biomarker Education & Disclosure
Mild Cognitive Impairment · Dementia; Alzheimer's Type (Etiology)
Primary: Participant Interest in PET Biomarker Disclosure — 73 Participants
N/A N=360 Alcohol Metabolism and Disease Risk in Asians
Healthy
Primary: Peak Number of Alcohol Drinks Consumed in a Day — 3.7; 4.2; 3.4; 3.0 drinks — p=.81
N/A N=1,479 Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48 — 2.9; 1.6; 2.7; 3.1 Score on a scale — p=0.049
N/A N=601 Genetic Testing for Type 2 Diabetes
Diabetes Mellitus
Primary: Weight — 103.8; 100.7 kg — p=0.44
Phase 3 N=1,468 Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48, as a Function of APOE ε4 Status in APOE4 Negatives…
N/A N=30 Triglyceride Effects on Blood Flow in the Human Brain
Alzheimer Disease
Primary: Cerebral Blood Flow Global — -2.2 ml/100g/min — p=.002
Phase 3 N=1,169 Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Cognition Disorders
Primary: Change From Baseline of the Preclinical Alzheimer Cognitive Composite (PACC) Score — -1.43; -1.13 score on a scale — p=0.260
N/A N=159 Cardiorespiratory Fitness, Apolipoprotein E Genotype, and Cognitive Functions: A Prospective Study
Aging · Cognitive Change
Primary: Changes in Inhibitory Performance: Stroop Task — 1.66; -29.85; 21.49; -20.13 ms
N/A N=117 Alzheimer's Prevention Through Exercise
Alzheimer's Disease
Primary: Amyloid Burden — 1.20; 1.22; 1.21; 1.22 Standard Uptake Value Ratio (SUVR)
N/A N=166 Risk Communication in African American Smokers
Lung Cancer
Primary: Motivation to Quit Smoking — 4.95; 3.30; 5.49; 4.52 units on a scale
Phase 2 N=26 Network-Level Mechanisms for Preclinical Alzheimer's Disease Development
APOE 4
Primary: Functional Connectivity Strengths of Neural Networks — 0.233; 0.318 Pearson coefficient — p=0.007567